Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases and a leading cause of hepatocellular carcinoma (HCC) in western countries. NAFLD does not only affect the liver but was shown to be a multisystem disease with increased risk of type 2 diabetes, kidney and cardiovascular diseases.
In honour of the International NASH Day (09 June), EASL Studio will host a special episode on the NAFLD pandemic, the discussions will include:
- Impact of lifestyles and policies for NAFLD and NASH prevention
- The complexity of NASH clinical trials
- Therapeutic approach in patients with HCC and NAFLD/NASH aetiology
This EASL Studio episode is supported by Novo Nordisk A/S and EISAI Europe Ltd.
ℹ️ Please click here to access the podcast version of this EASL Studio episode.